Brought to you by 
Pfizer gets Phase II brain cancer vaccine from Celldex; later returns rights
16 Nov 2021
Executive Summary
Pfizer received exclusive worldwide rights from Avant's wholly owned Celldex Therapeutics division to a Phase II CDX110 vaccine for glioblastoma multiforme (GBM) and other cancer vaccines that target the epidermal growth factor receptor variant vIII (EGFRvIII).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer gets Phase II brain cancer vaccine from Celldex; later returns rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice